Artery Doctor: This Just Changed Everything About Plaque and Heart Disease

Main Ideas

The conversation presents Dr. Anthony Jay’s argument that insulin resistance and persistently high insulin—not cholesterol alone—are central drivers of arterial plaque and heart disease. Host Thomas DeLauer asks questions and occasionally offers related ideas.

Many of Jay’s medical claims are controversial and differ from mainstream cardiovascular guidance. This summary reports his arguments rather than endorsing them.

Insulin Resistance, Sugar, and the Heart

Jay says the heart generally relies heavily on fat for energy, but repeated high-carbohydrate eating may encourage it to rely more on glucose. He argues that insulin resistance can then interfere with the heart and other tissues’ ability to use fuel, contributing to stress and plaque formation. In his view, cholesterol and fats found in plaque may be present as part of this process without being its original cause.

Risk-Factor Comparisons

Jay cites a study of roughly 28,000 people and reports the following hazard ratios in relation to early heart attacks:

• Insulin resistance: 6.4
• High blood pressure: 2.3
• Triglycerides: 2.1
• LDL: 1.38

He uses these figures to argue that research and medical discussion give too little attention to insulin resistance.

Heart Fuel Use and Athletic Performance

Jay says the heart continues to burn mostly fat even during strenuous activity. He points to ultrarunner Mike McKnight, who reportedly ran 118 miles without calories after years on a low-carbohydrate diet.

The speakers also discuss possible metabolic costs of chronically high glucose during endurance sports, as well as insulin’s role in heart growth and bodybuilding.

LDL and Lp(a)

Jay describes LDL primarily as a particle that transports fat around the body. He describes Lp(a) as LDL with an additional “tail” that binds oxidized material and carries it to the liver for removal—like a street sweeper.

In his account, Lp(a) can rise during infection or other oxidative stress, so he disputes the idea that its level is solely genetic or inherently harmful.

The Randle Cycle

The speakers discuss how cells use fat and carbohydrates as fuels. Jay says that when both are consumed together, insulin tends to favor glucose use and inhibit fat burning. He argues this may be more consequential in people with insulin resistance or metabolic dysfunction than in metabolically healthy people.

Exercise and Metabolic Flexibility

Jay says working muscles can take up glucose during exercise without insulin. He presents exercise, fasting, and—in some cases—reducing carbohydrate intake as ways people might improve insulin sensitivity and regain the ability to switch between fuels. He emphasizes that people vary in how well they tolerate carbohydrates.

Early Diet and Aging

Jay criticizes modern infant feeding and frequent carbohydrate-rich meals, and cites a 1939 study in which young children chose from a broad range of foods. He argues that aging can make people more susceptible to insulin resistance, even on a diet they tolerated when younger.

Tests and Plaque Scans

Jay recommends checking insulin alongside blood glucose and discusses HOMA-IR, which combines the two measurements. He gives a fasting insulin below 5 as his preferred target and says fasting glucose below 85 is favorable. These are his proposed optimal thresholds, not universal clinical standards.

He favors coronary artery calcium (CAC) scans, particularly for people over 50, and criticizes CT angiography (CCTA) and AI-assisted plaque readings as variable and open to interpretation.

Cholesterol Drugs and Plaque Imaging

Jay questions the benefits of PCSK9 drugs and statins, citing a reanalysis of the FOURIER trial and studies of coronary calcium. He also disputes the idea that calcified plaque is harmless.

These claims—including his interpretations of drug-trial mortality and scan reliability—are contested and should not be treated as established conclusions from the interview.

HDL and Overall Health

Jay views higher HDL more as a possible marker of healthy habits—such as good sleep and lower stress—than as a target to raise with medication. He says LDL can also reflect lifestyle or health conditions, not just diet.

Prevention, Evidence, and Self-Advocacy

Jay argues that heart disease develops over decades and emphasizes prevention and investigating metabolic health before disease is advanced. He criticizes pharmaceutical influence, inconsistent research, and media coverage, and encourages viewers to ask questions and seek information. He also advocates caution when assessing new food ingredients and products.

Practical Points Presented by the Guest

• Consider discussing fasting insulin and glucose with a healthcare professional; Jay says these can be used together to calculate HOMA-IR.
• Jay suggests that people over 50 consider CAC scanning to assess coronary calcium, while characterizing CCTA as less consistent. Imaging choices should be made with a clinician, weighing personal risks and benefits.
• Pay attention to exercise, dietary patterns, sleep, and stress as possible influences on metabolic health.
• Jay presents fasting and carbohydrate reduction as potential approaches, but does not prescribe one diet for everyone; he stresses individual differences.
• Treat the interview’s numerical claims and interpretations of drugs, scans, and studies as the guest’s views, not settled medical advice. Do not change prescribed medication or testing plans based on the video alone.

Speakers and Sources Mentioned

Speakers

• Thomas DeLauer — Host and interviewer; also delivers the LMNT/“Element” sponsor segment.
• Dr. Anthony Jay — Guest; author and researcher discussed in the interview.

People, Organizations, and Research Sources

• Ancel Keys — Discussed in connection with the cholesterol hypothesis and Mediterranean-diet framing.
• Mike McKnight — Ultrarunner cited as an example of prolonged exercise without calorie intake.
• Dr. Andrew Koutnik — Referenced in discussion of endurance athletes and glucose.
• Nick Norwitz — Mentioned regarding high cholesterol and Lp(a).
• Dr. Philip Ovadia and Ben Azadi — Cited in discussion of insulin targets and metabolic health.
• Matthew Budoff — Associated with a 2016 coronary-calcium study.
• Dean Ornish — Associated with a lifestyle study that the guest critiques.
• Boston University School of Medicine, Mayo Clinic, Florida State University, the National Lipid Association, the University of Alabama at Birmingham (UAB), the Oxford HOMA-IR method, the CDC, and the American Heart Association — Institutions or organizations mentioned.
• Research discussed: A roughly 28,000-person early-heart-attack risk study; the FOURIER trial and a reanalysis of it; a 1939 child diet-choice study; the 2016 Budoff CAC study; and a 2024 umbrella review of intermittent-fasting research.
• Products or companies mentioned: LMNT (rendered as “Element” in the subtitles), Repatha, HeartFlow, and Cleerly.